There are other TLR2 agonists that form TLR2–TLR1 heterodimers, and at least two of them (the synthetic molecules diprovocim and CU-T12-9) were developed as adjuvants for cancer immunotherapy, whereas another (polysaccharide A from Bacteroides fragilis) is produced by a member of the gut microbiome and associated with IL-10 production30–33. The gene discussed is TLR2; the disease is cancer.